ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Anidulafungin: Drug information

Anidulafungin: Drug information
(For additional information see "Anidulafungin: Patient drug information" and see "Anidulafungin: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Eraxis
Brand Names: Canada
  • Eraxis
Pharmacologic Category
  • Antifungal Agent, Parenteral;
  • Echinocandin
Dosing: Adult
Aspergillosis, invasive

Aspergillosis, invasive (including disseminated and extrapulmonary) (alternative agent) (off-label use):

Note: Reserve for salvage therapy, typically as part of an appropriate combination regimen. Monotherapy is further reserved for patients who are intolerant of or refractory to azoles and polyenes; for patients with severe or progressive infection, some experts use as initial therapy in combination with voriconazole (Ref).

IV: 200 mg on day 1, then 100 mg once daily (Ref).

Duration: When given as monotherapy, the minimum duration is 6 to 12 weeks depending on degree/duration of immunosuppression, disease site, and response to therapy (Ref); immunosuppressed patients may require more prolonged treatment (Ref). When given as part of a combination regimen, the optimal duration is uncertain. Some experts have given anidulafungin for ~2 weeks in combination with voriconazole before step-down to voriconazole monotherapy (Ref).

Candidiasis

Candidiasis:

Candidemia (neutropenic and nonneutropenic patients), including disseminated candidiasis: IV: 200 mg on day 1, then 100 mg once daily. Total duration (including oral step-down therapy) is ≥14 days after first negative blood culture and continues until signs/symptoms of candidemia and neutropenia, if present, have resolved; metastatic complications warrant a longer duration (Ref).

Cardiac device infection (including implantable cardiac defibrillator, pacemaker, ventricular assist device) (off-label use) : IV: 200 mg once daily; step down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures; total antifungal duration is ≥4 weeks after device removal for isolated generator pocket infection and ≥6 weeks after device removal for wire infection (Ref).

Chronic disseminated (hepatosplenic) (off-label use): IV: 200 mg on day 1, then 100 mg once daily for several weeks, followed by oral azole step-down therapy until lesion resolution and through periods of immunosuppression (Ref).

Empiric therapy, suspected invasive candidiasis (nonneutropenic ICU patients) (off-label use):

Note: Antifungal therapy is not routinely warranted for initial management of nonneutropenic patients with sepsis. Consider use for critically ill patients with unexplained fever or unexplained hypotension despite broad-spectrum antimicrobial therapy and risk factors for invasive candidiasis (eg, indwelling venous catheter, hemodialysis, trauma or burns, recent surgery, parenteral nutrition) (Ref).

IV: 200 mg on day 1, then 100 mg once daily. For those who improve, continue empiric antifungal therapy for 2 weeks; consider discontinuing after 4 to 5 days in patients with no evidence of invasive candidiasis and no clinical response (Ref).

Endocarditis, native or prosthetic valve (off-label use): IV: 200 mg once daily; step down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures; total antifungal duration is ≥6 weeks after valve replacement surgery, with longer duration for perivalvular abscesses, other complications, or a nonsurgical approach (Ref).

Esophageal, refractory disease (alternative agent):

Note: Reserve for fluconazole-refractory disease in patients who require IV therapy (eg, severe disease) (Ref).

IV: 200 mg once daily (Ref). Transition to an oral antifungal once patient tolerates oral intake if susceptibility allows; total antifungal duration is 14 to 28 days (Ref).

Intra-abdominal infection (eg, peritonitis, abdominal abscess): IV: 200 mg on day 1, then 100 mg once daily. Total duration (including oral step-down therapy) is ≥14 days and continues until source control and clinical resolution (Ref).

Oropharyngeal, refractory disease (alternative therapy) (off-label use):

Note: Reserve for fluconazole-refractory disease in patients who require IV therapy (eg, severe disease) (Ref).

IV: 200 mg on day 1, then 100 mg once daily. Transition to an oral antifungal once patient tolerates oral intake if susceptibility allows; total antifungal duration is 14 to 28 days (Ref).

Osteoarticular infection (osteomyelitis or septic arthritis) (off-label use): IV: 200 mg on day 1, then 100 mg once daily for ≥2 weeks; total duration of therapy (including oral step-down therapy) is 6 to 12 months for osteomyelitis and ≥6 weeks for septic arthritis (Ref).

Thrombophlebitis, suppurative (off-label use): IV: 200 mg once daily; continue antifungal therapy until catheter removed and thrombus resolved, and for ≥2 weeks after candidemia (if present) has cleared (Ref).

Neutropenic fever, empiric antifungal therapy

Neutropenic fever, empiric antifungal therapy (alternative agent) (off-label use):

Note: Recommended for patients with persistent or recurrent fever after ≥4 days of antimicrobial therapy when the duration of neutropenia is expected to exceed 7 days (Ref). Some experts reserve for patients without suspicion for mold infection (eg, pulmonary nodules) (Ref).

IV: 200 mg on day 1, then 100 mg once daily (Ref).

Prophylaxis against invasive fungal infections

Prophylaxis against invasive fungal infections (off-label use):

Hematologic malignancy or hematopoietic cell transplant (alternative agent):

Note: Some experts reserve for patients at low risk for mold infection (Ref).

IV: 200 mg on day 1, then 100 mg once daily. Duration is at least until resolution of neutropenia and varies based on degree and duration of immunosuppression (Ref).

Solid organ transplant (alternative agent): IV: 200 mg on day 1, then 100 mg once daily; duration varies based on patient risk factors and transplant center protocol (Ref).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: No dosage adjustment necessary for any degree of kidney impairment (Ref).

Hemodialysis, intermittent (thrice weekly): Not significantly dialyzed: No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Adult

No dosage adjustment necessary.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Anidulafungin: Pediatric drug information")

Aspergillosis, invasive

Aspergillosis, invasive (salvage therapy): Very limited data available: Infants, Children, and Adolescents: IV: Initial: 1.5 to 3 mg/kg/dose once on day 1; maximum initial dose: 200 mg/dose; on day 2 begin 0.75 to 1.5 mg/kg/dose once daily; maximum dose: 100 mg/dose. Duration of therapy should be individualized based on patient-specific factors including site of infection, immunosuppression, and response to therapy; minimum duration is 6 to 12 weeks (Ref): Note: Doses on the higher end of the provided range result in exposures similar to those observed in standard adult dose (Ref).

Candidemia; intra-abdominal or peritoneal candidiasis

Candidemia; intra-abdominal or peritoneal candidiasis: Infants, Children, and Adolescents: IV: Initial: 3 mg/kg/dose once on day 1; maximum initial dose: 200 mg/dose; on day 2 begin 1.5 mg/kg/dose once daily; maximum dose: 100 mg/dose (Ref). Duration of therapy should be individualized (based on deep-tissue foci, clinical response, etc); candidemia should be treated for a minimum of 14 days from the first negative blood culture and resolution of symptoms (Ref).

Dosing: Kidney Impairment: Pediatric

Altered kidney function: Infants, Children, and Adolescents: IV:

Mild to severe impairment: No dosage adjustment necessary in patients with any degree of renal impairment.

Hemodialysis: No dosage adjustment necessary.

Dosing: Hepatic Impairment: Pediatric

Infants, Children, and Adolescents: No dosage adjustment necessary in patients with any degree of hepatic impairment.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Cardiovascular: Hypotension (15%), hypertension (12%), peripheral edema (11%)

Central nervous system: Insomnia (15%)

Endocrine & metabolic: Hypokalemia (≤25%), hypomagnesemia (12%)

Gastrointestinal: Nausea (7% to 24%), diarrhea (9% to 18%), vomiting (7% to 18%)

Genitourinary: Urinary tract infection (15%)

Hepatic: Increased serum alkaline phosphatase (12%)

Infection: Bacteremia (18%)

Respiratory: Dyspnea (12%)

Miscellaneous: Fever (9% to 18%)

2% to 10%:

Cardiovascular: Deep vein thrombosis (10%), chest pain (5%)

Central nervous system: Confusion (8%), headache (8%), depression (6%)

Dermatologic: Decubitus ulcer (5%)

Endocrine & metabolic: Hypoglycemia (7%), dehydration (6%), hyperglycemia (6%), hyperkalemia (6%)

Gastrointestinal: Constipation (8%), dyspepsia (7%), abdominal pain (6%), oral candidiasis (5%)

Hematologic & oncologic: Anemia (8% to 9%), leukocytosis (5% to 8%), thrombocythemia (6%)

Hepatic: Increased serum transaminases (≤5%)

Infection: Sepsis (7%)

Neuromuscular & skeletal: Back pain (5%)

Renal: Increased serum creatinine (5%)

Respiratory: Pleural effusion (10%), cough (7%), pneumonia (6%), respiratory distress (6%)

<2%, postmarketing, and/or case reports: Anaphylactic shock, anaphylaxis, angioedema, atrial fibrillation, blood coagulation disorder, blurred vision, bronchospasm, cholestasis, clostridium infection, diaphoresis, dizziness, ECG abnormality (including ECG changes – prolonged QT interval), erythema, eye pain, flushing, hepatic insufficiency, hepatic necrosis, hepatitis, hot flash, increased amylase, increased blood urea nitrogen, increased creatine phosphokinase, increased gamma-glutamyl transferase, increased serum bilirubin, increased serum lipase, infusion related reaction, prolonged prothrombin time, pruritus, right bundle branch block, rigors, seizure, sinus arrhythmia, skin rash, thrombocytopenia, thrombophlebitis, urticaria, ventricular premature contractions, visual disturbance

Contraindications

Hypersensitivity to anidulafungin, other echinocandins, or any component of the formulation; known or suspected hereditary fructose intolerance.

Warnings/Precautions

Concerns related to adverse effects:

• Anaphylactic reactions: Severe hypersensitivity reactions, including anaphylactic reactions and anaphylactic shock, have been reported; immediate treatment for hypersensitivity reactions should be available. Discontinue treatment immediately if reactions occur.

• Hepatic effects: Elevated LFTs, hepatitis, and hepatic failure have been reported; monitor for progressive hepatic impairment if increased transaminase enzymes noted.

• Infusion reactions: Infusion reactions (eg, bronchospasm, dyspnea, flushing, hypotension, pruritus, rash, urticaria) may occur; do not exceed recommended rate of infusion.

Special populations:

• Obesity: Data suggest that clearance increases as a function of body weight (Dowell 2004). Based on data from another echinocandin, higher doses may be necessary in patients with obesity (Hall 2011).

Dosage form specific issues:

• Fructose: Some dosage forms may contain fructose; may precipitate a metabolic crisis (eg, life-threatening hepatic failure, hypoglycemia, hypophosphatemia, lactic acidosis) in patients with hereditary fructose intolerance. Obtain history of hereditary fructose intolerance prior to therapy.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous [preservative free]:

Eraxis: 50 mg (1 ea); 100 mg (1 ea) [contains polysorbate 80]

Generic Equivalent Available: US

No

Pricing: US

Solution (reconstituted) (Eraxis Intravenous)

50 mg (per each): $114.54

100 mg (per each): $229.07

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous:

Eraxis: 100 mg (1 ea) [contains polysorbate 80]

Administration: Adult

IV: For IV use only; infusion rate should not exceed 1.1 mg/minute (1.4 mL/minute or 84 mL/hour). Do not concurrently infuse with other medications or electrolytes.

Administration: Pediatric

Parenteral: IV: Infuse at ≤1.1 mg/minute (≤1.4 mL/minute or 84 mL/hour for concentration of 0.77 mg/mL). Do not concurrently infuse with other medications or electrolytes.

Use: Labeled Indications

Candidemia and other Candida infections: Treatment of candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) in adults and pediatric patients ≥1 month of age.

Candidiasis, esophageal, refractory disease: Treatment of esophageal candidiasis in adults.

Limitations of use: Dosage for the treatment of disseminated CNS or eye Candida infections has not been established. High relapse rates have occurred in patients treated for esophageal candidiasis.

Use: Off-Label: Adult

Aspergillosis, invasive (including disseminated and extrapulmonary); Candidiasis, cardiac device infection (including implantable cardiac defibrillator, pacemaker, ventricular assist device); Candidiasis, chronic disseminated (hepatosplenic); Candidiasis, empiric therapy, suspected invasive candidiasis (nonneutropenic ICU patients); Candidiasis, endocarditis, native or prosthetic valve; Candidiasis, oropharyngeal, refractory disease; Candidiasis, osteoarticular infections (osteomyelitis or septic arthritis); Candidiasis, thrombophlebitis, suppurative; Neutropenic fever, empiric antifungal therapy; Prophylaxis against invasive fungal infections

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. Risk X: Avoid combination

Pregnancy Considerations

Adverse effects were observed in animal reproduction studies. Other agents are currently preferred for the treatment of Candida infections in pregnant women (IDSA [Pappas 2016]).

Breastfeeding Considerations

It is not known if anidulafungin is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Monitoring Parameters

LFTs; anaphylaxis or infusion reactions (eg, bronchospasm, dyspnea, flushing, hypotension, pruritus, rash, urticaria).

Mechanism of Action

Noncompetitive inhibitor of 1,3-beta-D-glucan synthase resulting in reduced formation of 1,3-beta-D-glucan, an essential polysaccharide comprising 30% to 60% of Candida cell walls (absent in mammalian cells); decreased glucan content leads to osmotic instability and cellular lysis

Pharmacokinetics (Adult Data Unless Noted)

Distribution: 30 to 50 L.

Protein binding: >99%.

Metabolism: No hepatic metabolism observed; undergoes slow chemical hydrolysis to open-ring peptide-lacking antifungal activity.

Half-life elimination: Terminal: 40 to 50 hours.

Excretion: Feces (30%, 10% as unchanged drug); urine (<1%).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Obesity: Data suggest that clearance increases as a function of body weight (Dowell 2004).

Pediatric: Concentrations and exposure in infants, children, and adolescents receiving a 3 mg/kg loading dose followed by a 1.5 mg/kg maintenance dose were similar to those observed in adults receiving a 200 mg loading dose followed by a 100 mg maintenance dose.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Ecalta;
  • (AR) Argentina: Ecalta;
  • (AT) Austria: Anidulafungin accord | Anidulafungin ratiopharm | Anidulafungin stada | Ecalta;
  • (AU) Australia: Eraxis;
  • (BE) Belgium: Anidulafungin sandoz | Anidulafungin teva | Anidulafungine accord healthcare | Ecalta;
  • (BG) Bulgaria: Ecalta;
  • (BR) Brazil: Anidulafungina | Ecalta;
  • (CH) Switzerland: Anidulafungin labatec | Anidulafungin pfizer | Ecalta;
  • (CL) Chile: Andulgin | Anidulafungina | Ecalta;
  • (CO) Colombia: Ecalta | Gixofu;
  • (CZ) Czech Republic: Anidulafungin accord | Anidulafungin fresenius Kabi | Anidulafungin teva | Ecalta;
  • (DE) Germany: Anidulafungin accord | Anidulafungin fresenius Kabi | Anidulafungin hexal | Anidulafungin mylan | Anidulafungin Pharmore | Anidulafungin ratiopharm | Anidulafungin stada | Ecalta;
  • (DO) Dominican Republic: Ecalta;
  • (EC) Ecuador: Ecalta;
  • (EE) Estonia: Anidulafungin sandoz | Ecalta;
  • (EG) Egypt: Ecalata;
  • (ES) Spain: Anidulafungina accord | Anidulafungina normon | Anidulafungina stada | Anidulafungina teva | Ecalta;
  • (FI) Finland: Anidulafungin stada | Ecalta;
  • (FR) France: Ecalta;
  • (GB) United Kingdom: Anidulafungin teva | Ecalta;
  • (GR) Greece: Anidulafungin teva | Ecalta;
  • (HK) Hong Kong: Eraxis;
  • (HR) Croatia: Ecalta;
  • (HU) Hungary: Anidulafungin teva | Anidulafungina normon | Ecalta;
  • (ID) Indonesia: Ecalta;
  • (IE) Ireland: Anidulafungin teva | Ecalta;
  • (IN) India: Anidulan | B dula | Canidula | Dulaedge | Dulafix | Dulafun | Endfung | Eraxis | Fresofungin;
  • (IT) Italy: Anidulafungina medac | Anidulafungina teva;
  • (JO) Jordan: Ecalta | Nixara;
  • (KR) Korea, Republic of: Eraxis;
  • (KW) Kuwait: Ecalta;
  • (LB) Lebanon: Ecalta;
  • (LT) Lithuania: Ecalta | Eraxis;
  • (LV) Latvia: Anidulafungin sandoz | Ecalta;
  • (MX) Mexico: Equaltha | Eraxis;
  • (MY) Malaysia: Eraxis;
  • (NL) Netherlands: Anidulafungin teva | Anidulafungine | Anidulafungine accord | Anidulafungine cf | Ecalta;
  • (NO) Norway: Anidulafungin accord | Anidulafungin Pharmore | Ecalta;
  • (PE) Peru: Ecalta;
  • (PL) Poland: Anidulafungin fresenius Kabi | Anidulafungin sandoz | Anidulafungina accord;
  • (PR) Puerto Rico: Eraxis;
  • (PT) Portugal: Anidulafungin accord | Anidulafungina fresenius kabi | Anidulafungina teva | Ecalta;
  • (PY) Paraguay: Ecalta;
  • (QA) Qatar: Ecalta;
  • (RO) Romania: Anidulafungina accord | Anidulafungina teva | Ecalta;
  • (RU) Russian Federation: Eraxis;
  • (SA) Saudi Arabia: Ecalta | Lectra;
  • (SE) Sweden: Anidulafungin accord | Anidulafungin fresenius Kabi | Anidulafungin stada | Anidulafungin teva | Ecalta;
  • (SG) Singapore: Eraxis;
  • (SI) Slovenia: Anidulafungin accord | Anidulafungin teva | Ecalta;
  • (SK) Slovakia: Anidulafungin fresenius Kabi | Ecalta;
  • (TH) Thailand: Eraxis;
  • (TN) Tunisia: Ecalta;
  • (TR) Turkey: Eraxis | Figolyz | Funidul | Fuxesin | Mufines;
  • (TW) Taiwan: Eraxis;
  • (UA) Ukraine: Eraxis;
  • (VE) Venezuela, Bolivarian Republic of: Ecalta;
  • (ZA) South Africa: Arandi | Carixan | Eraxis
  1. Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
  2. Aslam S, Rotstein C; AST Infectious Disease Community of Practice. Candida infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13623. doi:10.1111/ctr.13623 [PubMed 31155770]
  3. Bradley JS and Nelson JD, eds. Nelson's Pediatric Antimicrobial Therapy. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.
  4. Burkhardt O, Kaever V, Burhenne H, Kielstein JT. Extended daily dialysis does not affect the pharmacokinetics of anidulafungin. Int J Antimicrob Agents. 2009;34(3):282-283. doi:10.1016/j.ijantimicag.2009.03.003 [PubMed 19369040]
  5. Candidiasis (Mucocutaneous). In: US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf. Updated May 26, 2020. Accessed June 16, 2021.
  6. Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm. [PubMed 6423951]
  7. Cohen-Wolkowiez M, Benjamin DK Jr, Piper L, et al. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther. 2011;89(5):702-707. [PubMed 21412233]
  8. De Rosa FG, Corcione S, Baietto L, et al. Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH. J Chemother. 2013;25(6):376-378. doi:10.1179/1973947813Y.0000000089 [PubMed 24090648]
  9. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004;44(6):590-598. doi:10.1177/0091270004265644 [PubMed 15145966]
  10. Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol. 2007;47(4):461-470. doi:10.1177/0091270006297227 [PubMed 17389555]
  11. Eraxis (anidulafungin) [prescribing information]. New York, NY: Roerig; May 2023.
  12. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y [PubMed 34599691]
  13. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  14. Fishman JA, Alexander BD. Prophylaxis of infections in solid organ transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 30, 2021.
  15. Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93. doi:10.1093/cid/cir073 [PubMed 21258094]
  16. Gould FK, Denning DW, Elliott TS, et al, “Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,” J Antimicrob Chemother, 2012, 67(2):269-89. [PubMed 22086858]
  17. Hall RG, Swancutt MA, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother. 2011;55(11):5107-5112. doi:10.1128/AAC.05193-11 [PubMed 21876061]
  18. Hope WW, Castagnola E, Groll AH, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18(suppl 7):38-52. [PubMed 23137136]
  19. Husain S, Camargo JF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13544. [PubMed 30900296]
  20. Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x [PubMed 12534540]
  21. Kauffman CA. Esophageal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed September 23, 2021c.
  22. Kauffman CA. Oropharyngeal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed June 17, 2021d.
  23. Leitner JM, Meyer B, Fuhrmann V, et al. Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration. J Antimicrob Chemother. 2011;66(4):880-884. doi:10.1093/jac/dkq545 [PubMed 21393208]
  24. Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
  25. Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81-89. doi:10.7326/M13-2508 [PubMed 25599346]
  26. Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. Surg Infect (Larchmt). 2017;18(1):1-76. doi:10.1089/sur.2016.261 [PubMed 28085573]
  27. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. doi:10.1093/cid/civ933 [PubMed 26679628]
  28. Patterson TF. Treatment and prevention of invasive aspergillosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 5, 2022.
  29. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326 [PubMed 27365388]
  30. Reboli AC, Rotstein C, Pappas PG, et al; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472-2482. doi:10.1056/NEJMoa066906 [PubMed 17568028]
  31. Refer to manufacturer's labeling.
  32. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8960):1312-1313. doi:10.1016/s0140-6736(95)90963-x [PubMed 7746084]
  33. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043-3054. doi:10.1200/JCO.18.00374 [PubMed 30179565]
  34. Trissel LA and Ogundele AB, “Compatibility of Anidulafungin With Other Drugs During Simulated Y-Site Administration,” Am J Health-Sys Pharm, 2005, 62:834-7.
  35. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed April 29, 2020.
  36. Vazquez JA. Candida osteoarticular infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 10, 2022a.
  37. Vazquez JA. Management of candidemia and invasive candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 27, 2022b.
  38. Warn PA, Livermore J, Howard S, et al. Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. Antimicrob Agents Chemother. 2012;56(2):708-714. [PubMed 22123680]
  39. Wingard JR. Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 10, 2022b.
  40. Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 4, 2021a.
  41. Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014;14(12):2758-2764. doi:10.1111/ajt.12963 [PubMed 25376267]
  42. Yáñez L, Insunza A, Ibarrondo P, et al. Experience with anidulafungin in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease. Transpl Infect Dis. 2015;17(5):761-767. doi:10.1111/tid.12429 [PubMed 26250790]
Topic 8744 Version 169.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟